Gilead to Acquire Arcellx for $7.8B in Cancer Therapy Deal

Gilead Sciences is expanding its presence in cancer therapy with the acquisition of Arcellx for $7.8 billion, Monday, February 23, 2026. The deal centers around an experimental CAR-T cell therapy, anito-cel, currently under review by the U.S. Food and Drug Administration for the treatment of multiple myeloma, a type of blood cancer.

The acquisition price represents a 79% premium over Arcellx’s closing stock price on Friday, February 21, 2026, valuing the company at $115 per share. Arcellx shareholders are also potentially eligible for an additional $5 per share contingent upon achieving cumulative global net sales of at least $6 billion for anito-cel through the end of year-end 2029.

CAR-T cell therapy represents a promising, though complex, approach to cancer treatment. It involves genetically modifying a patient’s own immune cells – T cells – to recognize and destroy cancer cells. This personalized approach offers potential benefits for patients who have not responded to other treatments. However, CAR-T therapy is not without risks, and can cause significant side effects.

The collaboration between Gilead’s Kite Pharma division and Arcellx began in 2022, focusing on the joint development and commercialization of anito-cel. Kite Pharma has been instrumental in bringing other CAR-T therapies to market, and this acquisition allows Gilead to fully integrate anito-cel into its oncology portfolio.

The FDA is expected to make a decision on the approval of anito-cel by December 23, 2026. If approved, Gilead anticipates that anito-cel will contribute to earnings per share starting in 2028 and beyond. This projection is based on the potential for significant sales, given the unmet need for effective treatments for multiple myeloma.

Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell. It is often characterized by periods of remission followed by relapse. While treatments like chemotherapy, radiation therapy, and stem cell transplantation can be effective, many patients eventually experience disease progression. New therapies, such as CAR-T cell therapy, offer hope for improved outcomes.

Gilead’s interest in Arcellx reflects a broader trend in the pharmaceutical industry: the acquisition of smaller biotechnology companies with promising drug pipelines. These acquisitions allow larger companies to quickly expand their portfolios and gain access to innovative technologies. The $7.8 billion price tag underscores the value placed on cell therapies, particularly those nearing potential FDA approval.

Prior to the acquisition announcement, Gilead already held approximately 12% ownership in Arcellx. This existing stake suggests a strong belief in the potential of Arcellx’s technology and the collaborative relationship between the two companies. The full acquisition solidifies Gilead’s commitment to the field of cell therapy and its position as a leader in oncology.

The market reacted swiftly to the news. Arcellx shares climbed 77.8% to $113.99 in premarket trading on Monday, February 23, 2026, while Gilead’s stock experienced a slight decrease of about 1% in premarket trading. This reflects investor confidence in Arcellx’s potential and a cautious assessment of the financial implications for Gilead.

The success of anito-cel will depend on several factors, including its efficacy, safety profile, and manufacturing scalability. CAR-T cell therapy is a complex and expensive treatment, and ensuring access for patients will be a key challenge. However, the potential benefits for patients with multiple myeloma are significant, and the acquisition of Arcellx positions Gilead to play a leading role in this evolving field.